SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA

Reuters

06-04

SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA

SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540052069"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540052069\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540052069?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540052069","market":"us","top_or_hot":-1,"title":"SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-04 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2460026573.USD","symbol_name":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL6cNSRr:1","article_id":"2540052069","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540052069","pubTimestamp":1749032451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA. SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China . The group received approval for its Calcium Gluconate and Sodium Chloride Injection , primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团","BK1191":"制药"},"translate_title":"SSY Group Ltd.的葡萄糖酸钙氯化钠注射液和氯化钾颗粒获得中国国家药监局的监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":0.9},"content_text":"SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n    \n\n        SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}